Grant: Operating Grant

Viruses that selectively kill tumor cells as a result of natural tropism or genetic engineering are termed oncolytic viruses. Some of these viruses are currently enrolled in clinical trials and show promising results. However, despite their destructive potency against tumor masses, consistent long-term regression has yet to be achieved. We have recently developed an approach to potentiate the killing capacity of oncolytic viruses and sustain tumor regression through the stimulation of robust antitumor responses. Furthermore, we have identified an anticancer drug that can simultaneously enhance oncolytic activity and antitumor immunity. This has led to dramatically improved therapeutic outcomes. Our proposed studies are designed to understand the mechanisms underlying this synergy.